Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

Aspirin is the most widely studied and prescribed antiplatelet agent for preventing serious vascular events, reducing the odds of such events among high vascular risk patients by about a quarter. Thienopyridine derivatives inhibit platelet activation by a different mechanism and so may be more effective.